GlassScriptPhysician profile
Emil Abramian
NPI 1689805616
$199,345.86
in general payments reported to CMS, 2019-2025
29 companies · $59K in 2025
The $59K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $260 · 2021: $438 · 2022: $912 · 2023: $6,333 · 2024: $132K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $133K · Travel and Lodging: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $11K · Consulting Fee: $3,675 · Gift: $14.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $133,250.00 |
| Travel and Lodging | $25,114.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,000.00 |
| Food and Beverage | $11,291.39 |
| Consulting Fee | $3,675.00 |
| Gift | $14.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $192,229.94 | 2021-2025 | Da Vinci Surgical System |
| Olympus Medical Systems Corporation | $3,375.00 | 2024 | |
| Pulmonx Corporation | $726.37 | 2021-2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Galvanize Therapeutics, INC | $618.73 | 2023-2025 | Aliya System |
| Glaxosmithkline, LLC. | $534.98 | 2019-2024 | Trelegy Ellipta |
| Veran Medical Technologies, INC. | $300.00 | 2024 | |
| Inari Medical, INC. | $208.85 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $203.79 | 2019-2023 | Symbicort |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.14 | 2019-2022 | |
| Olympus Corporation | $162.90 | 2023 | |
| Boston Scientific Corporation | $136.18 | 2023 | |
| Genzyme Corporation | $117.60 | 2021-2023 | |
| Covidien LP | $113.48 | 2019-2020 | |
| Inspire Medical Systems, INC. | $77.98 | 2023-2024 | Inspire |
| Erbe USA INC | $73.48 | 2022-2023 | Erbe Cryo2 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pinnacle Biologics, INC | $30.49 | 2019-2022 | |
| Philips North America LLC | $29.58 | 2021-2022 | |
| Harmony Biosciences LLC | $28.45 | 2022 | |
| Mallinckrodt Hospital Products INC. | $24.38 | 2022 | |
| Advanced Respiratory, INC | $23.12 | 2020 | |
| Mylan Specialty L.P. | $20.49 | 2019 | |
| Merck Sharp & Dohme LLC | $17.02 | 2020 | |
| United Therapeutics Corporation | $17.00 | 2022 | |
| Resmed Corp | $15.16 | 2020 | |
| Amgen INC. | $15.15 | 2022 | |
| Shire North American Group INC | $14.87 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.14 | 2021 | |
| Shionogi INC | $13.11 | 2022 | |
| Ambu INC. | $9.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emil Abramian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.